Campylobacter Infection Diagnosis and Management

Clinical Presentation and Diagnosis

• The American College of Gastroenterology recommends considering Campylobacter infection in patients with acute gastroenteritis, characterized by variable stool consistency, bright yellow coloration, and possible blood, as confirmed by positive Gastro PCR result 1, 2
• The European Society of Clinical Microbiology and Infectious Diseases notes that Campylobacter jejuni/coli causes acute gastroenteritis with a highly variable clinical presentation, ranging from watery diarrhea to bloody, mucoid stools 1, 3
• The Infectious Diseases Society of America states that variable stool patterns, such as Bristol 4-6, are characteristic of Campylobacter enteritis, which can present as watery, mucoid, or bloody diarrhea 1, 3

Treatment Approach

• The American College of Gastroenterology recommends supportive care alone for immunocompetent patients with non-severe Campylobacter infection, while antimicrobial therapy is warranted in severe cases, immunocompromised patients, or those with signs of systemic illness or bacteremia 1, 4, 6
• The European Society of Clinical Microbiology and Infectious Diseases suggests azithromycin as the preferred first-line agent due to increasing fluoroquinolone resistance in Campylobacter, with a recommended dosage of 500 mg on day 1, then 250 mg daily for 4 days 2, 4

Complications and Monitoring

• The Centers for Disease Control and Prevention notes that Guillain-Barré syndrome is a rare but concerning late complication of Campylobacter infection, occurring in a small percentage of cases 1, 3
• The American Gastroenterological Association states that post-infectious IBS develops in 10-14% of patients following Campylobacter infection, with IBS-D or IBS-M being most common, and can persist for months to years after the acute infection resolves 5
• The Infectious Diseases Society of America recommends tracking clinical improvement over the next 3-7 days, monitoring frequency and character of stools, temperature normalization, and watching for persistent symptoms beyond 14 days 2, 3, 5